Proprotein convertase subtilisin/kexin 9 inhibition in patients with familial hypercholesterolemia: Initial clinical...

Area of Science:

• Cardiology
• Genetics
• Pharmacology

Background:

• Familial hypercholesterolemia (FH) patients often do not reach LDL-c goals despite optimal therapy.
• PCSK9 inhibitors demonstrate significant LDL-c reductions and good safety in clinical trials.
• Real-world efficacy and safety data for PCSK9 inhibitors in FH are limited.

Purpose of the Study:

• To evaluate the efficacy and safety of PCSK9 inhibitors in a clinical setting for FH patients.
• To describe the real-world effectiveness of PCSK9 inhibitors in managing LDL-c levels in FH.
• To document the side effect profile of PCSK9 inhibitors in a diverse FH patient population.

Main Methods:

• A registry-based study of consecutive FH patients initiating PCSK9 inhibitor therapy at a university hospital lipid clinic.
• Inclusion of both genetically confirmed and clinically diagnosed heterozygous FH (heFH) and homozygous FH (hoFH) patients.
• Analysis of LDL-c reduction, treatment adherence, and reported side effects.

Main Results:

• PCSK9 inhibitors achieved a mean additional LDL-c reduction of 55% ± 21% in 83 FH patients.
• Heterozygous FH patients experienced greater LDL-c reduction (56%) compared to homozygous FH patients (38%).
• Side effects were reported by 39% of patients, with flu-like symptoms and injection site reactions being most common; 8% discontinued treatment.

Conclusions:

• PCSK9 inhibition in a clinical setting provides comparable LDL-c reduction to clinical trials.
• Real-world use of PCSK9 inhibitors in FH patients is associated with a higher incidence of side effects than observed in clinical trials.
• These findings highlight the importance of monitoring side effects in routine clinical practice for FH patients on PCSK9 inhibitors.